HEALTH CATALYST INC (HCAT) Stock Fundamental Analysis
USA - NASDAQ:HCAT - US42225T1079 - Common Stock
2.925 USD
-0.12 (-4.1%)
Overall HCAT gets a fundamental rating of 2 out of 10. We evaluated HCAT against 35 industry peers in the Health Care Technology industry. Both the profitability and financial health of HCAT have multiple concerns. HCAT has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
HCAT had positive earnings in the past year.
In the past year HCAT has reported a negative cash flow from operations.
In the past 5 years HCAT always reported negative net income.
In the past 5 years HCAT reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -16.25%, HCAT is in line with its industry, outperforming 48.57% of the companies in the same industry.
HCAT has a Return On Equity (-28.81%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.25% | ||
| ROE | -28.81% | ||
| ROIC | N/A |
ROA(3y)-14.4%
ROA(5y)-16.3%
ROE(3y)-27.85%
ROE(5y)-30.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
HCAT's Gross Margin of 46.00% is on the low side compared to the rest of the industry. HCAT is outperformed by 65.71% of its industry peers.
HCAT's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for HCAT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y-2.4%
2. Health
2.1 Basic Checks
HCAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HCAT has more shares outstanding
HCAT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for HCAT is higher compared to a year ago.
2.2 Solvency
HCAT has an Altman-Z score of -1.96. This is a bad value and indicates that HCAT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of HCAT (-1.96) is worse than 68.57% of its industry peers.
HCAT has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
HCAT has a worse Debt to Equity ratio (0.44) than 62.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.96 |
ROIC/WACCN/A
WACC8.02%
2.3 Liquidity
A Current Ratio of 1.83 indicates that HCAT should not have too much problems paying its short term obligations.
HCAT's Current ratio of 1.83 is on the low side compared to the rest of the industry. HCAT is outperformed by 62.86% of its industry peers.
HCAT has a Quick Ratio of 1.83. This is a normal value and indicates that HCAT is financially healthy and should not expect problems in meeting its short term obligations.
HCAT has a Quick ratio of 1.83. This is in the lower half of the industry: HCAT underperforms 62.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 |
3. Growth
3.1 Past
HCAT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -27.27%.
HCAT shows a small growth in Revenue. In the last year, the Revenue has grown by 5.55%.
The Revenue has been growing by 14.63% on average over the past years. This is quite good.
EPS 1Y (TTM)-27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
Revenue 1Y (TTM)5.55%
Revenue growth 3Y8.22%
Revenue growth 5Y14.63%
Sales Q2Q%6.35%
3.2 Future
HCAT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.01% yearly.
Based on estimates for the next years, HCAT will show a small growth in Revenue. The Revenue will grow by 1.17% on average per year.
EPS Next Y-19.86%
EPS Next 2Y25.04%
EPS Next 3Y27.03%
EPS Next 5Y7.01%
Revenue Next Year1.83%
Revenue Next 2Y0.79%
Revenue Next 3Y1.17%
Revenue Next 5Y1.17%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 18.28, HCAT is valued on the expensive side.
Compared to the rest of the industry, the Price/Earnings ratio of HCAT indicates a rather cheap valuation: HCAT is cheaper than 94.29% of the companies listed in the same industry.
HCAT's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.13.
A Price/Forward Earnings ratio of 6.68 indicates a rather cheap valuation of HCAT.
HCAT's Price/Forward Earnings ratio is rather cheap when compared to the industry. HCAT is cheaper than 100.00% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of HCAT to the average of the S&P500 Index (22.35), we can say HCAT is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.28 | ||
| Fwd PE | 6.68 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
HCAT's earnings are expected to grow with 27.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.04%
EPS Next 3Y27.03%
5. Dividend
5.1 Amount
No dividends for HCAT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:HCAT (11/6/2025, 1:33:23 PM)
2.925
-0.12 (-4.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners78.61%
Inst Owner Change-1.92%
Ins Owners3.42%
Ins Owner Change9.22%
Market Cap205.83M
Revenue(TTM)316.09M
Net Income(TTM)-100119000
Analysts73.33
Price Target4.53 (54.87%)
Short Float %9.99%
Short Ratio10.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)202.94%
Min EPS beat(2)15.68%
Max EPS beat(2)390.2%
EPS beat(4)2
Avg EPS beat(4)82.29%
Min EPS beat(4)-46.95%
Max EPS beat(4)390.2%
EPS beat(8)6
Avg EPS beat(8)423.36%
EPS beat(12)10
Avg EPS beat(12)426.62%
EPS beat(16)14
Avg EPS beat(16)329.36%
Revenue beat(2)0
Avg Revenue beat(2)-1.74%
Min Revenue beat(2)-1.82%
Max Revenue beat(2)-1.66%
Revenue beat(4)0
Avg Revenue beat(4)-1.85%
Min Revenue beat(4)-2.04%
Max Revenue beat(4)-1.66%
Revenue beat(8)1
Avg Revenue beat(8)-1.34%
Revenue beat(12)3
Avg Revenue beat(12)-0.88%
Revenue beat(16)5
Avg Revenue beat(16)-0.65%
PT rev (1m)-2.44%
PT rev (3m)-36.51%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.55%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.95%
Revenue NQ rev (1m)-2.12%
Revenue NQ rev (3m)-10.81%
Revenue NY rev (1m)-0.64%
Revenue NY rev (3m)-6.62%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.28 | ||
| Fwd PE | 6.68 | ||
| P/S | 0.65 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.59 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)0.16
EY5.47%
EPS(NY)0.44
Fwd EY14.97%
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS4.49
BVpS4.94
TBVpS-0.52
PEG (NY)N/A
PEG (5Y)N/A
Graham Number4.22
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.25% | ||
| ROE | -28.81% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46% | ||
| FCFM | N/A |
ROA(3y)-14.4%
ROA(5y)-16.3%
ROE(3y)-27.85%
ROE(5y)-30.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.71%
GM growth 5Y-2.4%
F-Score5
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 44.35% | ||
| Cap/Sales | 6.35% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 | ||
| Altman-Z | -1.96 |
F-Score5
WACC8.02%
ROIC/WACCN/A
Cap/Depr(3y)36.51%
Cap/Depr(5y)42.93%
Cap/Sales(3y)5.5%
Cap/Sales(5y)5.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
EPS Next Y-19.86%
EPS Next 2Y25.04%
EPS Next 3Y27.03%
EPS Next 5Y7.01%
Revenue 1Y (TTM)5.55%
Revenue growth 3Y8.22%
Revenue growth 5Y14.63%
Sales Q2Q%6.35%
Revenue Next Year1.83%
Revenue Next 2Y0.79%
Revenue Next 3Y1.17%
Revenue Next 5Y1.17%
EBIT growth 1Y32.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year162.03%
EBIT Next 3Y43.03%
EBIT Next 5Y29.42%
FCF growth 1Y57.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.28%
OCF growth 3YN/A
OCF growth 5YN/A
HEALTH CATALYST INC / HCAT FAQ
What is the fundamental rating for HCAT stock?
ChartMill assigns a fundamental rating of 2 / 10 to HCAT.
What is the valuation status for HCAT stock?
ChartMill assigns a valuation rating of 4 / 10 to HEALTH CATALYST INC (HCAT). This can be considered as Fairly Valued.
Can you provide the profitability details for HEALTH CATALYST INC?
HEALTH CATALYST INC (HCAT) has a profitability rating of 1 / 10.
Can you provide the financial health for HCAT stock?
The financial health rating of HEALTH CATALYST INC (HCAT) is 1 / 10.